Fennec Pharmaceuticals Inc. entered into a License and Supply Agreement with Norgine Pharma UK Limited, granting Norgine an exclusive license to commercialize PEDMARQSI in certain territories, with upfront payment of $40 million and potential milestone and royalty payments.